EFM
VIR icon

E Fund Management’s Vir Biotechnology VIR Stock Holding History

E Fund Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$198K Buy
19,384
+2,488
+15% +$23.7K ﹤0.01% 457
2026
Q1 		$151K Buy
+16,896
New +$135K ﹤0.01% 461
2025
Q2 		$74.1K Sell
14,698
-1,295
-8% -$6.94K ﹤0.01% 381
2025
Q1 		$104K Buy
+15,993
New +$142K 0.01% 380
2024
Q4 		– Sell
-11,170
Closed -$83.7K – 414
2024
Q3 		$83.7K Buy
+11,170
New +$97K ﹤0.01% 344
2024
Q2 		– Sell
-20,761
Closed -$210K – 381
2024
Q1 		$210K Sell
20,761
-664
-3% -$6.76K 0.01% 337
2023
Q4 		$216K Sell
21,425
-5,557
-21% -$50.8K 0.01% 270
2023
Q3 		$253K Buy
26,982
+10,220
+61% +$146K 0.02% 224
2023
Q2 		$411K Sell
16,762
-319
-2% -$8.01K 0.03% 161
2023
Q1 		$397K Buy
17,081
+903
+6% +$23.1K 0.03% 168
2022
Q4 		$409K Sell
16,178
-5,106
-24% -$125K 0.03% 177
2022
Q3 		$410K Buy
21,284
+2,345
+12% +$59.6K 0.04% 178
2022
Q2 		$482K Buy
18,939
+6,656
+54% +$155K 0.04% 148
2022
Q1 		$316K Buy
+12,283
New +$364K 0.01% 184

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

E Fund Management's VIR Position: Q2 2026 in Review

E Fund Management increased its Vir Biotechnology (VIR) stake by 15% in Q2 2026, buying an estimated $23.7K and bringing the position to 19,384 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #457.

E Fund Management first reported a position in VIR in Q1 2022 and has held it in 14 quarters since. The position peaked at $482K in Q2 2022. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • E Fund Management held 19,384 shares of Vir Biotechnology worth $198K as of Q2 2026.
  • E Fund Management bought 2,488 Vir Biotechnology shares in Q2 2026, an estimated $23.7K.
  • Vir Biotechnology made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #457 holding.
  • E Fund Management first reported a position in Vir Biotechnology in Q1 2022 and has held it in 14 quarters since.
  • E Fund Management's Vir Biotechnology position peaked at $482K in Q2 2022.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.